<DOC>
	<DOCNO>NCT00546325</DOCNO>
	<brief_summary>Primary : To assess effect rimonabant HbA1c patient Type 2 diabetes overweight obese ( Body Mass Index ( BMI ) &gt; 27 kg/m² BMI &lt; 40 kg/m² ) , uncontrolled HbA1c ( 7.0 % - 9.0 % inclusive ) currently maximal tolerate dos two Oral Anti Diabetic medication - Metformin ( Met ) Sulfonylurea ( SU ) . Secondary : To assess effect rimonabant Anthropometric measure , Glucose measure , Lipid measure , Other measure change quality life</brief_summary>
	<brief_title>REASSURE : The Effect Rimonabant HbA1c Overweight Obese Patients With Type 2 Diabetes Not Adequately Controlled 2 Oral Antidiabetic Agents</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>Rimonabant</mesh_term>
	<criteria>List Inclusion Exclusion criterion : History Type 2 diabetes HbA1c 7 % 9 % ( inclusive ) BMI ≥ 27kg/m² BMI ≤ 40kg/m² Currently take Metformin Sulfonylurea . Uncontrolled serious psychiatric illness major depression Current use antidepressant Severe renal impairment ( creatinine clearance le 30ml/min ) Severe hepatic impairment know investigator Aspartate Aminotransferase and/or Alanine Aminotransferase &gt; 3 time Upper Limit Normal Patient treat epilepsy Pregnant breastfeed woman Women childbearing potential protected effective contraception Hypersentivity/intolerance rimonabant excipents Presence condition , current anticipate investigator 's opinion would compromise patient 's safety Use insulin longer 1 week within 4 week prior screen Chronic use systemic corticosteriods Use glitazone therapy , glucagonlike peptide dipeptidyl peptidase IV History drug alcohol abuse wihtin last three year Heart failure class IIIIV ( New York Heart Association classification ) Severe hypertension Adminstration follow medication : phentermine , amphetamine , orlistat , sibutramine , herbal remedy Use nonlipid agent know affect lipid metabolism : retinoids , antiretrovirals , hormone replacement therapy contain estrogen , cyclosporin , thiazolidinediones ( glitazones ) , fish oil , plant sterol Use ketoconazole , itraconazole , ritonavir , clarithromycin , rifampicin , phenytoin , phenobarbitone , carbamazepine St John 's Wort Participation clinical study within 4 week prior randomisation Patients involve exist weight loss program Presence chronic hepatitis Use , misuse , substance abuse Marijuana hashish user History gastrointestinal surgery weight loss purpose schedule surgery within duration expect participation study History presence bulimia laxative abuse NonEnglish speak The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>